This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.
Trial Name: Name of Trial: A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
Protocol ID: ECOG 1Z11
Age 18 years of age and older
Patients must be female and post-menopausal
Patients must have estrogen and/or progesterone receptor positive histologically confirmed Stage I-III adenocarcinoma of the breast
Patients must have completed recommended local therapy and adjuvant chemotherapy for breast cancer
Patients must not have received prior Aromatase Inhibitor (AI) therapy with exemestane, letrozole, or anastrozole as adjuvant therapy for prevention of breast cancer.Prior tamoxifen as adjuvant therapy or for prevention is allowed.
Plan to treat with anastrozole for at least 12 months
Patients must not have prior history of ovarian, endometrial, or fallopian tube carcinoma, and/or primary peritoneal carcinomatosis
Patients must not be currently taking (or have taken in the past 6 months) ongoing daily analgesic medication for active, chronic conditions (i.e. rheumatoid arthritis, carpal tunnel syndrome, tenosynovitis, systemic lupus erythrmatosus, gout, fibromyalgia, or severe osteoarthritis involving the hands, writs, hips, knees, feet or ankles).(Note: patients taking daily low dose aspirin are allowed to participate in this trial).
Patients must not have a prior history of deep vein thrombosis (DVT) or pulmonary embolism in the past 5 years
Patients must meet required laboratory values
Enrollment: 1000 will participate
There is no direct benefit to you by taking part in this study.We expect that the information from this study will help doctors learn more about the side effects of anastrozole when given as a treatment for breast cancer and patients’ symptoms.This information could help doctors develop new treatments for side effects that can help cancer patients in the future.
These clinical trial overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Oncology Clinical Research Coordinator, Beth Knetter at 715-847-2353 or 1-800-283-2881, ext.72353.